Your browser doesn't support javascript.
loading
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression.
Geng, Chuandong; Zhang, Man-Chao; Manyam, Ganiraju C; Vykoukal, Jody V; Fahrmann, Johannes F; Peng, Shan; Wu, Cheng; Park, Sanghee; Kondraganti, Shakuntala; Wang, Daoqi; Robinson, Brian D; Loda, Massimo; Barbieri, Christopher E; Yap, Timothy A; Corn, Paul G; Hanash, Samir; Broom, Bradley M; Pilié, Patrick G; Thompson, Timothy C.
Afiliação
  • Geng C; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Zhang MC; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Manyam GC; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Vykoukal JV; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Fahrmann JF; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Peng S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wu C; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Park S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kondraganti S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wang D; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Robinson BD; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York.
  • Loda M; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.
  • Barbieri CE; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.
  • Yap TA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
  • Corn PG; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York.
  • Hanash S; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
  • Broom BM; Department of Urology, Weill Cornell Medicine, New York, New York.
  • Pilié PG; Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Thompson TC; Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.
Clin Cancer Res ; 29(21): 4464-4478, 2023 11 01.
Article em En | MEDLINE | ID: mdl-37581614
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article